Le Lézard
Classified in: Health, Business

RegeneRx Releases Annual Letter to Shareholders



ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter is focused on updating shareholders on the Company's product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months. To view the letter, please go to www.regenerx.com.

Forward Looking Statements
Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking statements in this shareholder letter include, but are not limited to, statements regarding our strategic and research partnerships, future royalty and milestone payments, regulatory applications and approvals, the development of our drug candidates, the use of our drug candidates to treat various conditions, our growth strategy, and our financial needs. The proposed clinical trials and costs and resources to support such trials, as well as the other forward-looking statements, are expectations and estimates based upon information obtained and calculated by the Company at this time and are subject to change. Moreover, there is no guarantee any of these trials will be successful or confirm previous clinical results. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2016, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this shareholder letter represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE RegeneRx Biopharmaceuticals, Inc.


These press releases may also interest you

at 03:03
Open Road Alliance, a philanthropic initiative that seeks to preserve impact in the social sector, today announced the launch of Open Road Ventures, a new fund that will disburse at least $50 million in loans to nonprofits and social enterprises over...

at 03:00
MOUNTAIN VIEW, Calif., Feb. 21, 2018 /PRNewswire-PRWeb/ -- Guardian Analytics, the market leader in real-time behavioral analytics and machine learning solutions for banking payment fraud detection, enterprise B2B portal fraud, together with Fintel,...

at 03:00
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that it has entered into an exclusive worldwide license agreement with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc. ("Catalent") to...

at 02:39
Getlink reports results for 2017. Jacques Gounon, Chairman & CEO of Getlink, comments on results and outlook. Watch video interview and read transcript:...

at 02:02
Korea Mobile Society, Co. Ltd. (hereby referred to as KMS) and Microsoft Korea (hereby referred to as MS) has signed a MOU for the development, establishment and technology support of Bingo Music based on Azure media service that associated with...

at 02:00
Eleven National Winners from Germany were named at an exclusive event held at the British Embassy in Berlin last night by Europe's largest business competition, the European Business Awards, sponsored by RSM.        (Photo:...




News published on 7 december 2017 at 14:33 and distributed by: